CAC progression assessed in 467 IBD patients without known ASCVD

This multicenter retrospective cohort study included 467 patients with inflammatory bowel disease who did not have known atherosclerotic cardiovascular disease. The population was assessed for coronary artery calcium (CAC) progression compared to baseline CAC levels. The mean follow-up interval was 21.2 months.

The primary outcome measured the prognostic value of CAC progression beyond baseline CAC. Specific main results, including hazard ratios, confidence intervals, or event rates, were not reported in the provided data. Consequently, the magnitude of any association between CAC progression and clinical outcomes remains unknown based on this input.

Safety and tolerability data were not reported for adverse events, serious adverse events, discontinuations, or general tolerability. Funding sources and conflicts of interest were also not reported. The study limitations regarding the absence of reported main results and safety data restrict the ability to draw definitive clinical conclusions from this specific evidence set.